Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

Zobrazit celou dokumentaci

N1230000

Norfloxacin

European Pharmacopoeia (EP) Reference Standard

Synonyma:

1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazino-3-quinolinecarboxylic acid

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C16H18FN3O3
Číslo CAS:
70458-96-7
Molekulová hmotnost:
319.33
MDL number:
MFCD00079532
UNSPSC Code:
41116107
PubChem Substance ID:
329818530
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

norfloxacin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

InChI key

OGJPXUAPXNRGGI-UHFFFAOYSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Norfloxacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Norfloxacin blocks DNA replication by interfering with an ATP-induced structural transition of DNA complexed with DNA gyrase (topoisomerase).
Mode of action: inhibits bacterial DNA replication
Antimicrobial spectrum: Gram-negative bacteria; less effective against Gram-positive bacteria

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

N1230010

Norfloxacin impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001015

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001301

Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard

1471506

Norfloxacin, United States Pharmacopeia (USP) Reference Standard

1471517

Norfloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1471550

Norfloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1471583

Norfloxacin Related Compound H, United States Pharmacopeia (USP) Reference Standard

1471619

Norfloxacin Related Compound K, United States Pharmacopeia (USP) Reference Standard

BP670

Norfloxacin, British Pharmacopoeia (BP) Reference Standard

PHR2233

Norfloxacin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 1

1 of 1

Trimethoprim ≥98.5%

Sigma-Aldrich

T7883

Trimethoprim

Nour El-Houda Jlili et al.
Journal of medical microbiology, 63(Pt 2), 195-202 (2013-11-07)
The prevalence of plasmid-mediated quinolone resistance genes [qnr, aac(6')-Ib-cr and qepA] was sought among Enterobacteriaceae strains obtained from the Children's Hospital of Tunis (Tunisia). Non-duplicate isolates (n = 278) with resistance to extended-spectrum cephalosporins and collected in 2003, 2007, 2008 and 2009
G E Stein
The American journal of medicine, 82(6B), 18-21 (1987-06-26)
The pharmacokinetic profile of norfloxacin, an oral fluoroquinolone, is more complex than that of many antibacterial agents. Following administration of a 400-mg dose, peak serum concentrations of 1.5 to 2.0 micrograms/ml are achieved within one to two hours. The drug
A J Schaeffer
European urology, 17 Suppl 1, 19-23 (1990-01-01)
In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b.i.d. for 7-90 days. The majority of the patients were men, and many were elderly. Underlying diseases included nephrolithiasis, pyelonephritis, prostatism, bacterial
C Lee et al.
The American journal of medicine, 82(6B), 27-34 (1987-06-26)
The in vitro spectrum and potency of norfloxacin against both aerobic gram-negative and gram-positive bacteria, its limited activity against anaerobes, and the apparent difficulty organisms have in acquiring resistance to it, have provided a rationale for the clinical development of
Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.